Drugs / INCB57643
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06619522 | Sep 2024 → May 2025 | myelofibrosis | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB57643 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06619522 ↗ |
| Action | Inhibit | “BET Inhibitor” NCT06619522 ↗ |
| Route | Oral | “Given orally” NCT06619522 ↗ |